GeneTether Therapeutics Inc. (GNTTF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GeneTether Therapeutics Inc. (GNTTF) trades at $0.01. GeneTether Therapeutics Inc. is a biotechnology company focused on developing precision gene editing technologies for human therapeutics. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for GNTTF: GNTTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNTTF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GNTTF: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →GeneTether Therapeutics Inc. (GNTTF) Healthcare & Pipeline Overview
GeneTether Therapeutics Inc. is a genetic medicines company specializing in high-efficiency precision gene editing using its proprietary GeneTether platform. Focused on rare, monogenic diseases, particularly those affecting the kidney and skin, the company aims to improve existing genome editing technologies like CRISPR-Cas, operating within the competitive biotechnology sector.
What Is the Investment Thesis for GNTTF?
GeneTether Therapeutics Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful development and commercialization of its GeneTether platform. A key value driver is the platform's ability to enhance the efficiency of existing gene-editing technologies, potentially leading to more effective therapies for rare, monogenic diseases. Upcoming catalysts include the progression of its pipeline candidates through preclinical and clinical trials, with initial data readouts expected in the next 12-24 months. Successful trial outcomes could significantly increase the company's valuation. However, the company's negative P/E ratio of -0.66 reflects its current lack of profitability and reliance on future success. The absence of a dividend further underscores the speculative nature of the investment. The company's OTC listing also presents liquidity and regulatory risks.
Based on FMP financials and quantitative analysis
GNTTF Key Highlights
GeneTether Therapeutics Inc. is focused on developing high-efficiency precision gene editing for human therapeutics applications.
- The company's core technology is the GeneTether platform, designed to enhance the efficiency of existing genome editing technologies.
- GeneTether is building a discovery pipeline targeting rare, monogenic diseases, with an initial focus on diseases affecting the kidney and skin.
- The company's P/E ratio is -0.66, reflecting its current lack of profitability.
- GeneTether does not currently offer a dividend.
Who Are GNTTF's Competitors?
GNTTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | $58.90 | -1.52% | $5.68B | 44 |
| EDIT Editas Medicine, Inc. | $2.94 | -9.54% | $451M | — |
| NTLA Intellia Therapeutics, Inc. | $12.44 | -6.33% | $1.74B | — |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNTTF's Key Strengths?
Proprietary GeneTether platform.
- Focus on high-efficiency gene editing.
- Targeting rare, monogenic diseases.
- Potential for curative therapies.
What Are GNTTF's Weaknesses?
Early-stage development company.
- Limited financial resources.
- High dependence on technology success.
- Lack of approved products.
What Could Drive GNTTF Stock Higher?
Preclinical data release for lead kidney disease program in Q4 2026.
- Initiation of Phase 1 clinical trial for skin disease therapy in H1 2027.
- Expansion of the GeneTether platform to new gene-editing technologies.
- Strategic partnerships with pharmaceutical companies for co-development.
What Are the Key Risks for GNTTF?
Financial-distress signal — its Altman Z-Score of -0.32 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-42.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure of clinical trials for pipeline candidates.
- Competition from established gene-editing companies.
- Regulatory hurdles for gene therapies.
- Limited financial resources and dependence on future funding.
- Risks associated with OTC market listing, including liquidity and transparency.
What Are the Growth Opportunities for GNTTF?
- Advancement of Pipeline Candidates: GeneTether's primary growth opportunity lies in the successful development and advancement of its pipeline candidates through preclinical and clinical trials. The company is focused on rare, monogenic diseases of the kidney and skin. Positive data from these trials could lead to regulatory approvals and commercialization of novel therapies, driving revenue growth. The timeline for this growth opportunity is dependent on the progress of clinical trials, with potential for initial product launches within the next 3-5 years. The market for gene editing therapies is projected to reach $7.5 billion by 2030.
- Expansion of the GeneTether Platform: The GeneTether platform has the potential to be applied to a wide range of gene-editing technologies, including CRISPR-Cas, TALENs, and ZFNs. Expanding the platform's capabilities and applications could open up new therapeutic areas and partnership opportunities. This growth opportunity involves ongoing research and development efforts to enhance the platform's efficiency and versatility. The market for gene editing technologies is expected to grow significantly in the coming years, driven by increasing demand for precision medicine.
- Strategic Partnerships and Collaborations: GeneTether can pursue strategic partnerships and collaborations with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships could provide access to additional resources, expertise, and funding. The timeline for this growth opportunity is dependent on the company's ability to establish mutually beneficial relationships with potential partners. The market for strategic partnerships in the biotechnology sector is highly competitive, but successful collaborations can significantly enhance a company's growth prospects.
- Targeting Additional Rare Diseases: GeneTether's initial focus is on rare, monogenic diseases of the kidney and skin, but the company can expand its pipeline to target other rare diseases with significant unmet medical needs. This growth opportunity involves identifying promising targets and developing gene-editing therapies using the GeneTether platform. The market for rare disease therapies is growing rapidly, driven by increasing awareness and regulatory incentives. The timeline for this growth opportunity is dependent on the company's ability to identify and validate new targets.
- Out-licensing and Technology Transfer: GeneTether can generate revenue by out-licensing its GeneTether platform to other companies or research institutions for use in their own gene-editing programs. This growth opportunity involves establishing licensing agreements and providing technical support to licensees. The market for gene-editing technologies is highly competitive, but GeneTether's unique platform could attract significant interest from potential licensees. The timeline for this growth opportunity is dependent on the company's ability to market and promote its technology effectively.
What Are GNTTF's Competitive Advantages?
- Proprietary GeneTether platform enhances gene-editing efficiency.
- Focus on rare, monogenic diseases with unmet medical needs.
- Patent protection for its gene-editing technologies.
- Expertise in gene editing and genetic medicines.
What Does GNTTF Do?
GeneTether Therapeutics Inc. is a biotechnology company dedicated to the advancement of genetic medicines through high-efficiency precision gene editing. The company was founded with the goal of creating innovative therapies for human diseases, particularly those with a genetic basis. Its core technology is the GeneTether platform, designed to significantly enhance the efficiency of existing genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs. This platform aims to improve the precision and effectiveness of gene editing, potentially leading to more successful therapeutic outcomes. GeneTether is focused on building a robust discovery pipeline targeting rare, monogenic diseases. The company's initial focus is on diseases affecting the kidney and skin, areas with significant unmet medical needs. By concentrating on these specific therapeutic areas, GeneTether aims to leverage its platform to develop targeted and effective treatments. The company's strategy involves identifying promising targets within these disease areas and utilizing the GeneTether platform to create gene-editing therapies. These therapies are designed to correct the underlying genetic defects that cause these diseases, offering the potential for long-term or even curative treatments. GeneTether is actively engaged in research and development activities to advance its pipeline of therapeutic candidates through preclinical and clinical stages. GeneTether Therapeutics Inc. operates primarily in the biotechnology sector, focusing on gene editing and genetic medicines. Its competitive positioning relies on the unique capabilities of the GeneTether platform and its focus on specific therapeutic areas. The company aims to establish itself as a leader in the field of precision gene editing for human therapeutics.
What Products and Services Does GNTTF Offer?
- Develops high-efficiency precision gene editing technologies.
- Creates gene-editing therapies based on the proprietary GeneTether platform.
- Focuses on rare, monogenic diseases of the kidney and skin.
- Enhances the efficiency of genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs.
- Builds a discovery pipeline for the treatment of genetic diseases.
- Conducts research and development to advance therapeutic candidates through preclinical and clinical stages.
How Does GNTTF Make Money?
- Develops and patents gene-editing technologies.
- Creates therapeutic candidates targeting specific genetic diseases.
- Out-licenses its technology to other companies.
- Generates revenue through potential future sales of approved therapies.
What Industry Does GNTTF Operate In?
GeneTether Therapeutics Inc. operates within the rapidly evolving biotechnology industry, specifically in the gene editing and genetic medicines market. This market is characterized by high growth potential, driven by advancements in gene editing technologies and increasing demand for therapies targeting genetic diseases. The competitive landscape includes established players like CRISPR Therapeutics and Editas Medicine, as well as numerous smaller companies and academic institutions. GeneTether's success depends on its ability to differentiate itself through its proprietary GeneTether platform and its focus on specific therapeutic areas.
Who Are GNTTF's Key Customers?
- Potentially patients with rare, monogenic diseases.
- Pharmaceutical companies seeking to license gene-editing technologies.
- Research institutions interested in using the GeneTether platform.
Key Financial Metrics
Return on equity for GeneTether Therapeutics Inc. stands at -42.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -14.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 36.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.6%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
GeneTether Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. GNTTF has traded publicly since 2022.
Financial Health
GeneTether Therapeutics Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.32 places it in the distress zone, a signal of elevated financial risk.
GNTTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary GeneTether platform.
- Focus on high-efficiency gene editing.
- Targeting rare, monogenic diseases.
- Potential for curative therapies.
Bear Case
- Early-stage development company.
- Limited financial resources.
- High dependence on technology success.
- Lack of approved products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
GNTTF Latest News
No recent news available for GNTTF.
GNTTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNTTF.
Price Targets
Wall Street price target analysis for GNTTF.
GNTTF MoonshotScore
What does this score mean?
The MoonshotScore rates GNTTF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
GNTTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GeneTether Therapeutics Inc. may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial information available to the public, and there may be less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Potential for fraud and manipulation.
- Lack of regulatory oversight.
- Limited liquidity and wide bid-ask spreads.
- Higher risk of delisting or going out of business.
- Verify the company's management team and their track record.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any regulatory filings or legal proceedings.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Presence of a professional website and investor relations materials.
- Independent audits of financial statements (if available).
- Experienced management team with relevant industry expertise.
- Clear business plan and strategy.
- Active engagement with investors and the public.
What Investors Ask About GeneTether Therapeutics Inc. (GNTTF) — Healthcare
What does GeneTether Therapeutics Inc. do?
GeneTether Therapeutics Inc. is a biotechnology company focused on developing high-efficiency precision gene editing technologies for human therapeutics. The company's core technology is the GeneTether platform, designed to enhance the efficiency of existing genome editing technologies like CRISPR-Cas. GeneTether is building a discovery pipeline targeting rare, monogenic diseases, with an initial focus on diseases affecting the kidney and skin.
What are the main risks for GNTTF?
GeneTether Therapeutics Inc. faces several key risks inherent to its business and industry. As a biotechnology company, the success of its pipeline candidates is highly uncertain, and clinical trials may fail to demonstrate efficacy or safety. The company also faces competition from established gene-editing companies with greater resources and more advanced technologies.
What are the key factors to evaluate for GNTTF?
Evaluate GNTTF on fundamentals, analyst consensus, and risk factors. GeneTether Therapeutics Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does GNTTF data refresh on this page?
GNTTF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GNTTF's recent stock price performance?
GeneTether Therapeutics Inc. (GNTTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary GeneTether platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNTTF overvalued or undervalued right now?
GeneTether Therapeutics Inc. (GNTTF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GNTTF before investing?
Before investing in GeneTether Therapeutics Inc. (GNTTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GNTTF to a portfolio?
Key strength of GeneTether Therapeutics Inc. (GNTTF): Proprietary GeneTether platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing.
- AI analysis is pending and may provide further insights.